These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25723736)

  • 1. Defining and managing expectations for early immunotherapy cancer trials.
    Kieber-Emmons T; Pennisi A; Lane A; Siegel E; Cannon M; Monzavi-Karbassi B; Makhoul I
    Rev Recent Clin Trials; 2015; 10(1):47-60. PubMed ID: 25723736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing Expectations in the Transition to Proof of Concept Studies.
    Kieber-Emmons T; Makhoul I; Pennisi A; Siegel ER; Emanuel PD; Monzavi-Karbassi B; Steplewski Z; Beck JT; Hutchins LF
    Rev Recent Clin Trials; 2017; 12(2):111-123. PubMed ID: 28325150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.
    Mandrekar SJ
    Am Soc Clin Oncol Educ Book; 2014; ():e107-10. PubMed ID: 24857087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing oncologic benefit in clinical trials of immunotherapy agents.
    Hales RK; Banchereau J; Ribas A; Tarhini AA; Weber JS; Fox BA; Drake CG
    Ann Oncol; 2010 Oct; 21(10):1944-1951. PubMed ID: 20237004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-specific active immunotherapy for ovarian cancer.
    Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief K; Nijman HW
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007287. PubMed ID: 20091627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
    Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common cancers--immunotherapy and multidisciplinary therapy: Parts III and IV.
    Quan WD; Palackdharry CS
    Dis Mon; 1997 Nov; 43(11):745-808. PubMed ID: 9400420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
    Messer K; Natarajan L; Ball ED; Lane TA
    Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.
    Mellman I; Hubbard-Lucey VM; Tontonoz MJ; Kalos MD; Chen DS; Allison JP; Drake CG; Levitsky H; Lonberg N; van der Burg SH; Fearon DT; Wherry EJ; Lowy I; Vonderheide RH; Hwu P
    Cancer Immunol Res; 2016 Apr; 4(4):279-88. PubMed ID: 27036972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials.
    Guo B; Li D; Yuan Y
    Pharm Stat; 2018 Sep; 17(5):527-540. PubMed ID: 29882388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
    Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
    Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
    Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase I cancer trials methodology].
    Le Tourneau C; Faivre S; Raymond E; Diéras V
    Bull Cancer; 2007 Nov; 94(11):943-51. PubMed ID: 18055311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.